Earnings Preview: What to Expect From Bio-Techne's Report

Company Overview - Bio-Techne Corporation (TECH) is headquartered in Minneapolis, Minnesota, and specializes in developing, manufacturing, and selling life science reagents, instruments, and services for research, diagnostics, and bioprocessing markets, with a market cap of $9.3 billion [1] Earnings Expectations - Analysts expect TECH to report a profit of $0.37 per share on a diluted basis for the fiscal first quarter of 2026, which is unchanged from the same quarter last year [2] - For the full fiscal year, analysts project an EPS of $1.76, reflecting a 2.9% increase from $1.71 in fiscal 2025, and an expected rise to $2 in fiscal 2027, representing a 13.6% year-over-year growth [3] Stock Performance - TECH stock has underperformed the S&P 500 Index, which gained 14.4% over the past 52 weeks, with TECH shares down 18.7% during the same period [4] - The stock also underperformed the Health Care Select Sector SPDR Fund, which saw a 7.8% loss in the same timeframe [4] Recent Financial Results - On August 6, TECH reported its Q4 results, with an adjusted EPS of $0.53, surpassing Wall Street expectations of $0.50, and revenue of $317 million, exceeding forecasts of $315.4 million [5] Analyst Ratings - The consensus opinion on TECH stock is bullish, with a "Strong Buy" rating overall; out of 16 analysts, 11 recommend "Strong Buy," one suggests "Moderate Buy," and four give a "Hold" rating [6] - The average analyst price target for TECH is $66.77, indicating a potential upside of 11.9% from current levels [6]